Healthcare Nov 19, 2020 09:33 AM (GMT+8) · EqualOcean
Billion Europe health on November 19, Baiji Shenzhou announced recently that according to the judgment of the independent data monitoring committee (DMC), the rationale of bazaar? Vs. docetaxel for patients with second-line or third-line locally advanced or metastatic non-small-cell lung cancer (NSCLC) who developed disease progression after platinum chemotherapy was evaluated by the independent data monitoring committee (DMC) In the pre planned interim analysis of 303 clinical trial, the primary end point of overall survival (OS) was achieved in the population of patients with intention to treat. The safety data of bazaar? Are consistent with known risks and no new safety warnings appear.
Related companies: